An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502952-30-00

Acronym

67953964MDD1006

Enrollment

Registered

2023-06-30

Start date

2023-08-04

Completion date

2024-08-13

Last updated

2024-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adult Participants

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026